Rockefeller Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-665
| Closed | -$13.4K | – | 4812 |
|
|
2026
Q1 | $13.4K | Buy |
665
+532
| +400% | +$8.57K | ﹤0.01% | 3864 |
|
|
2025
Q4 | $2.15K | Buy |
+133
| New | +$1.76K | ﹤0.01% | 4302 |
|
|
2023
Q1 | – | Sell |
-1,323
| Closed | -$8K | – | 2988 |
|
|
2022
Q4 | $8K | Hold |
1,323
| – | – | ﹤0.01% | 3185 |
|
|
2022
Q3 | $19K | Hold |
1,323
| – | – | ﹤0.01% | 2798 |
|
|
2022
Q2 | $13K | Buy |
1,323
+73
| +6% | +$805 | ﹤0.01% | 2984 |
|
|
2022
Q1 | $18K | Hold |
1,250
| – | – | ﹤0.01% | 2764 |
|
|
2021
Q4 | $16K | Hold |
1,250
| – | – | ﹤0.01% | 2749 |
|
|
2021
Q3 | $21K | Buy |
1,250
+250
| +25% | +$5.07K | ﹤0.01% | 2569 |
|
|
2021
Q2 | $23K | Hold |
1,000
| – | – | ﹤0.01% | 2427 |
|
|
2021
Q1 | $25K | Hold |
1,000
| – | – | ﹤0.01% | 2185 |
|
|
2020
Q4 | $18K | Sell |
1,000
-500
| -33% | -$8.57K | ﹤0.01% | 2045 |
|
|
2020
Q3 | $18K | Hold |
1,500
| – | – | ﹤0.01% | 1830 |
|
|
2020
Q2 | $18K | Hold |
1,500
| – | – | ﹤0.01% | 1705 |
|
|
2020
Q1 | $11K | Hold |
1,500
| – | – | ﹤0.01% | 1715 |
|
|
2019
Q4 | $27K | Buy |
+1,500
| New | +$19.6K | ﹤0.01% | 1304 |
|
Other funds holding KALV
Rockefeller Capital Management's KALV Position: Q2 2026 in Review
Rockefeller Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 665 shares — an estimated $13.4K sold.
Rockefeller Capital Management first reported a position in KALV in Q4 2019 and held it in 15 quarters. The position peaked at $27K in Q4 2019. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Rockefeller Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Rockefeller Capital Management sold 665 KalVista Pharmaceuticals shares in Q2 2026, an estimated $13.4K.
- Rockefeller Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 15 quarters.
- Rockefeller Capital Management's KalVista Pharmaceuticals position peaked at $27K in Q4 2019.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.